FDA approves eribulin mesylate for the treatment of unresectable or advanced liposarcoma

On 28 January, 2016 the US Food and Drug Administration (FDA) approved a chemotherapy drug eribulin mesylate (Halaven) for the treatment of unresectable or advanced liposarcoma. This treatment is approved for patients who received prior chemotherapy that contained an anthracycline. Read more here.